Top

Current Rheumatology Reports

Published in:

01-09-2020 | Antiphospholipid Syndrome | Antiphospholipid Syndrome (S Zuily, Section Editor)

Management of Non-criteria Manifestations in Antiphospholipid Syndrome

Authors: Eleni Xourgia, Maria G. Tektonidou

Published in: Current Rheumatology Reports | Issue 9/2020

Abstract

Purpose of the Review

To review the available evidence on the management of a variety of non-criteria manifestations in antiphospholipid syndrome (APS), including valvular disease, alveolar hemorrhage, thrombocytopenia, hemolytic anemia, APS nephropathy, skin ulcers, livedo reticularis, cognitive dysfunction, and epilepsy.

Recent Findings

Current treatment relies on low-level evidence and mainly on expert consensus due to the rarity and the heterogeneity of non-criteria APS manifestations and the diversity in management approaches. Conventional anticoagulation and/or antiplatelet APS treatment do not adequately control most of non-criteria manifestations. Increasing knowledge about the contribution of inflammatory in addition to, or independently of, thrombotic mechanisms in non-criteria APS manifestations provides insight into the potential effect of novel therapies targeting B-cells, mammalian target of rapamycin, neutrophil, and complement or interferon pathways.

Summary

Existing evidence is limited by lack of high-quality studies. Better understanding of the pathophysiology and clinical phenotypes of APS and well-designed prospective studies of homogenous populations are needed to provide evidence-based recommendations for the management of non-criteria APS manifestations.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH. 2006;4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x.CrossRefPubMed

Abreu MM, Danowski A, Wahl DG, Amigo M-C, Tektonidou M, Pacheco MS, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmun Rev. 2015;14:401–14. https://doi.org/10.1016/j.autrev.2015.01.002.CrossRefPubMed

Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010–21. https://doi.org/10.1056/NEJMra1705454.CrossRefPubMed

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296–304. https://doi.org/10.1136/annrheumdis-2019-215213.CrossRefPubMed

Chighizola CB, Andreoli L, Gerosa M, Tincani A, Ruffatti A, Meroni PL. The treatment of anti-phospholipid syndrome: a comprehensive clinical approach. J Autoimmun. 2018;90:1–27. https://doi.org/10.1016/j.jaut.2018.02.003.CrossRefPubMed

Ugolini-Lopes MR, Criado PR, Parsi K, Kucukkaya RD, Amigo M-C, Tektonidou MG, et al. Treatment of non-criteria manifestations in antiphospholipid syndrome. In: Erkan D, Lockshin MD, editors. Antiphospholipid Syndr. Cham: Springer International Publishing; 2017. p. 247–66. https://doi.org/10.1007/978-3-319-55442-6_13.CrossRef

Andrade D, Tektonidou M. Emerging therapies in antiphospholipid syndrome. Curr Rheumatol Rep. 2016;18:22. https://doi.org/10.1007/s11926-016-0566-z.CrossRefPubMed

Sevim E, Willis R, Erkan D. Is there a role for immunosuppression in antiphospholipid syndrome? Hematol Am Soc Hematol Educ Program. 2019;2019:426–32. https://doi.org/10.1182/hematology.2019000073.CrossRef

Cervera R, Tektonidou MG, Espinosa G, Cabral AR, González EB, Erkan D, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20:165–73. https://doi.org/10.1177/0961203310395051.CrossRefPubMed

10.

Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007;6:379–86. https://doi.org/10.1016/j.autrev.2007.01.003.CrossRefPubMed

11.

Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol 2019;10. Doi:fimmu.2019.00941.

12.

• Tufano A, Minno MNDD, Guida A, Lembo M, Minno GD, Galderisi M. Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies. Semin Thromb Hemost. 2019;45:468–77. https://doi.org/10.1055/s-0039-1692702This review describes the major cardiac manifestations of APS, the role of cardiac imaging in the detection of subclinical lesions and treatment approaches.CrossRefPubMed

13.

García-Torres R, Amigo MC, de la Rosa A, Morón A, Reyes PA. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus. 1996;5:56–61. https://doi.org/10.1177/096120339600500111.CrossRefPubMed

14.

Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A, et al. Libman-sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus. 1996;5:196–205. https://doi.org/10.1177/096120339600500306.CrossRefPubMed

15.

Lockshin M, Tenedios F, Petri M, McCarty G, Forastiero R, Krilis S, et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus. 2003;12:518–23. https://doi.org/10.1191/0961203303lu391oa.CrossRefPubMed

16.

Espínola-Zavaleta N, Vargas-Barrón J, Colmenares-Galvis T, Cruz-Cruz F, Romero-Cárdenas A, Keirns C, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J. 1999;137:973–8. https://doi.org/10.1016/s0002-8703(99)70424-2.CrossRefPubMed

17.

Yuriditsky E, Torres J, Izmirly PM, Belmont HM. Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review. Lupus. 2018;27:2269–73. https://doi.org/10.1177/0961203318804876.CrossRefPubMed

18.

Kampolis C, Tektonidou M, Moyssakis I, Tzelepis GE, Moutsopoulos H, Vlachoyiannopoulos PG. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. Semin Arthritis Rheum. 2014;43:558–65. https://doi.org/10.1016/j.semarthrit.2013.07.016.CrossRefPubMed

19.

Erdozain J-G, Ruiz-Irastorza G, Segura M-I, Amigo M-C, Espinosa G, Pomar J-L, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res. 2012;64:1256–60. https://doi.org/10.1002/acr.21670.CrossRef

20.

Colli A, Mestres CA, Espinosa G, Plasín MA, Pomar JL, Font J, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2010;37:154–8. https://doi.org/10.1016/j.ejcts.2009.06.046.CrossRef

21.

Mishra PK, Khazi FM, Yiu P, Billing JS. Severe antiphospholipid syndrome and cardiac surgery: perioperative management. Asian Cardiovasc Thorac Ann. 2016;24:473–6. https://doi.org/10.1177/0218492315577879.CrossRefPubMed

22.

Gorki H, Malinovski V, Stanbridge RDL. The antiphospholipid syndrome and heart valve surgery. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2008;33:168–81. https://doi.org/10.1016/j.ejcts.2007.11.004.CrossRef

23.

Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum. 2005;35:154–65. https://doi.org/10.1016/j.semarthrit.2005.05.006.CrossRefPubMed

24.

Stoots SA, Lief L, Erkan D. Clinical insights into diffuse alveolar hemorrhage in antiphospholipid syndrome. Curr Rheumatol Rep. 2019;21:56. https://doi.org/10.1007/s11926-019-0852-7.CrossRefPubMedPubMedCentral

25.

Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011–8. https://doi.org/10.1136/annrheumdis-2013-204838.CrossRefPubMed

26.

Maioli G, Calabrese G, Capsoni F, Gerosa M, Meroni PL, Chighizola CB. Lung disease in antiphospholipid syndrome. Semin Respir Crit Care Med. 2019;40:278–94. https://doi.org/10.1055/s-0039-1683994.CrossRefPubMed

27.

Scheiman Elazary A, Cohen MJ, Aamar S, Dranitzki Z, Tayer-Shifman O, Mevorach D, et al. Pulmonary hemorrhage in antiphospholipid antibody syndrome. J Rheumatol. 2012;39:1628–31. https://doi.org/10.3899/jrheum.120205.CrossRefPubMed

28.

Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum. 2015;44:652–7. https://doi.org/10.1016/j.semarthrit.2014.10.013.CrossRefPubMed

29.

Cartin-Ceba R, Peikert T, Ashrani A, Keogh K, Wylam ME, Ytterberg S, et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care Res. 2014;66:301–10. https://doi.org/10.1002/acr.22109.CrossRef

30.

Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Rodriguez-Ariza A, Cuadrado MJ. Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep. 2012;14:87–94. https://doi.org/10.1007/s11926-011-0222-6.CrossRefPubMed

31.

• Watanabe T, Oku K, Amengual O, Hisada R, Ohmura K, Nakagawa I, et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus. 2018;27:225–34. https://doi.org/10.1177/0961203317716787This study described the protective role of statins against thrombosis in a retrospective analysis of data from 152 SLE patients with positive antiphospholipid antibodies between 1997 and 2014.CrossRefPubMed

32.

Altunal C, Agalar F, Agalar C, Daphan C, Saygun O, Aydinuraz K, et al. The effect of simvastatin on pulmonary damage in experimental peritonitis in rats. Indian J Surg. 2015;77:370–5. https://doi.org/10.1007/s12262-013-0845-0.CrossRefPubMed

33.

Huang L-K, Tsai M-J, Tsai H-C, Chao H-S, Lin F-C, Chang S-C. Statin-induced lung injury: diagnostic clue and outcome. Postgrad Med J. 2013;89:14–9. https://doi.org/10.1136/postgradmedj-2011-130209.CrossRefPubMed

34.

Yazici A, Yazirli B, Erkan D. Belimumab in primary antiphospholipid syndrome. Lupus. 2017;26:1123–4. https://doi.org/10.1177/0961203316682102.CrossRefPubMed

35.

McGuire W c., Dill S, Fischer A. Eculizumab for refractory catastrophic antiphospholipid syndrome complicated by life-threatening diffuse alveolar hemorrhage. C33 CASE Rep. AUTOIMMUNE Inflamm. LUNG Dis., American Thoracic Society; 2019, p. A4569–A4569. Doi:https://doi.org/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A4569.

36.

Vreede AP, Bockenstedt PL, McCune WJ, Knight JS. Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol. 2019;31:231–40. https://doi.org/10.1097/BOR.0000000000000595.CrossRefPubMedPubMedCentral

37.

Uthman I, Godeau B, Taher A, Khamashta M. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008;22:187–94. https://doi.org/10.1016/j.blre.2008.03.005.CrossRefPubMed

38.

Uthman I, Noureldine MHA, Ruiz-Irastorza G, Khamashta M. Management of antiphospholipid syndrome. Ann Rheum Dis. 2019;78:155–61. https://doi.org/10.1136/annrheumdis-2018-213846.CrossRefPubMed

39.

Krause I, Blank M, Fraser A, Lorber M, Stojanovich L, Rovensky J, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology. 2005;210:749–54. https://doi.org/10.1016/j.imbio.2005.10.005.CrossRefPubMed

40.

Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2019;18:102395. https://doi.org/10.1016/j.autrev.2019.102395.CrossRefPubMed

41.

Demetrio Pablo R, Muñoz P, López-Hoyos M, Calvo V, Riancho L, Martínez-Taboada VM. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria. Med Clin (Barc). 2017;148:394–400. https://doi.org/10.1016/j.medcli.2016.11.026.CrossRef

42.

• Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheum. 2018;48:117–20. https://doi.org/10.1016/j.semarthrit.2017.12.006The study showed that extra-criteria manifestations were more frequently found among APS patients with higher adjusted Global APS Score.CrossRefPubMed

43.

Artim-Esen B, Diz-Küçükkaya R, İnanç M. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17:14. https://doi.org/10.1007/s11926-014-0494-8.CrossRefPubMed

44.

Martinuzzo ME, Maclouf J, Carreras LO, Lévy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 1993;70:667.CrossRefPubMed

45.

Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54:2558–67. https://doi.org/10.1002/art.21968.CrossRefPubMed

46.

Galli M, Daldossi M, Barbui T. Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1994;71:571–5.CrossRefPubMed

47.

Swain F, Bird R. How I approach new onset thrombocytopenia. Platelets. 2019;31:285–90. https://doi.org/10.1080/09537104.2019.1637835.CrossRefPubMed

48.

Cuadrado MJ, Mujic F, Munoz E, Khamashta M, Hughes G. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis. 1997;56:194–6.CrossRefPubMedPubMedCentral

49.

• Abe N, Oku K, Amengual O, Fujieda Y, Kato M, Bohgaki T, et al. Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: a systematic review and meta-analysis. Mod Rheumatol. 2020;30:116–24. https://doi.org/10.1080/14397595.2018.1558934This is a systematic review of the efficacy and safety of treatments for antiphospholipid antibody- associated thrombocytopenia showing no association between glucocorticoids and thrombosis or between splenectomy and hemorrhage.CrossRefPubMed

50.

Erkan D, Vega J, Ramón G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71. https://doi.org/10.1002/art.37759.CrossRefPubMed

51.

Sciascia S, Radin M, Cecchi I, Rubini E, Bazzan M, Roccatello D. Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. Semin Arthritis Rheum. 2019;48:741–4. https://doi.org/10.1016/j.semarthrit.2018.04.001.CrossRefPubMed

52.

Alkaabi JK, Alkindi S, Riyami NA, Zia F, Balla LMA, Balla SM. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus. 2012;21:1571–4. https://doi.org/10.1177/0961203312463621.CrossRefPubMed

53.

Moreno Martínez MJ, Gallego P, Moreno Ramos MJ. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus. Reumatol Clin. 2016;12:57. https://doi.org/10.1016/j.reuma.2015.04.004.CrossRefPubMed

54.

Lusa A, Carlson A. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series. Lupus. 2018;27:1723–8. https://doi.org/10.1177/0961203318770023.CrossRefPubMed

55.

Boulon C, Vircoulon M, Constans J. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events. Lupus. 2016;25:331. https://doi.org/10.1177/0961203315608257.CrossRefPubMed

56.

Guitton Z, Terriou L, Lega J-C, Nove-Josserand R, Hie M, Amoura Z, et al. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatol Oxf Engl. 2018;57:1432–8. https://doi.org/10.1093/rheumatology/key119.CrossRef

57.

LaMoreaux B, Barbar-Smiley F, Ardoin S, Madhoun H. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist. Semin Arthritis Rheum. 2016;45:e10–2. https://doi.org/10.1016/j.semarthrit.2015.07.008.CrossRefPubMed

58.

Cervera R, Piette J-C, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27. https://doi.org/10.1002/art.10187.CrossRefPubMed

59.

Rottem M, Krause I, Fraser A, Stojanovich L, Rovensky J, Shoenfeld Y. Autoimmune hemolytic anaemia in the antiphospholipid syndrome. Lupus. 2006;15:473–7. https://doi.org/10.1191/0961203306lu2336oa.CrossRefPubMed

60.

•• Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody–positive patients: results from the antiphospholipid syndrome alliance for clinical trials and international clinical database and repository. Arthritis Care Res. 2019;71:134–41. https://doi.org/10.1002/acr.23584This study compares the clinical, laboratory, and treatment characteristics of antiphospholipid antibody positive individuals with or without SLE in a large international registry.CrossRef

61.

Tektonidou MG, Ioannidis JP, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM Mon J Assoc Physicians. 2000;93:523–30. https://doi.org/10.1093/qjmed/93.8.523.CrossRef

62.

Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42:417–23. https://doi.org/10.1016/j.semarthrit.2012.05.005.CrossRefPubMed

63.

Barron N, Arenas-Osuna J, Medina G, Cruz-Dominguez MP, González-Romero F, Velásques-García JA, et al. Splenectomy in systemic lupus erythematosus and autoimmune hematologic disease: a comparative analysis. Clin Rheumatol. 2018;37:943–8. https://doi.org/10.1007/s10067-018-3979-4.CrossRefPubMed

64.

Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, et al. 14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96. https://doi.org/10.1016/j.autrev.2014.01.053.CrossRefPubMed

65.

Brodsky RA. Warm autoimmune hemolytic anemia. N Engl J Med. 2019;381:647–54. https://doi.org/10.1056/NEJMcp1900554.CrossRefPubMed

66.

Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2003;12:633–5. https://doi.org/10.1191/0961203303lu419cr.CrossRefPubMed

67.

Amigo MC, Garcia-Torres R, Robles M, Bochicchio T, Reyes PA. Renal involvement in primary antiphospholipid syndrome. J Rheumatol. 1992;19:1181–5.PubMed

68.

Nochy D, Daugas E, Droz D, Beaufils H, Grünfeld JP, Piette JC, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol JASN. 1999;10:507–18.PubMed

69.

Daugas E, Nochy D, Huong DLT, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol JASN. 2002;13:42–52.PubMed

70.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50:2569–79. https://doi.org/10.1002/art.20433.CrossRefPubMed

71.

Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol. 2008;35:1983–8.PubMed

72.

Silvariño R, Sant F, Espinosa G, Pons-Estel G, Solé M, Cervera R, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011;20:721–9. https://doi.org/10.1177/0961203310397410.CrossRefPubMed

73.

Miranda JM, Jara LJ, Calleja C, Saavedra MA, Bustamante RM, Angeles U. Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE). Reumatol Clínica. 2009;5:209–13. https://doi.org/10.1016/j.reuma.2008.12.011.CrossRef

74.

Bienaimé F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int. 2017;91:34–44. https://doi.org/10.1016/j.kint.2016.06.026.CrossRefPubMed

75.

Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Ann Rheum Dis. 2019;78:1004–6. https://doi.org/10.1136/annrheumdis-2018-214559.CrossRefPubMed

76.

Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82. https://doi.org/10.1136/annrheumdis-2012-201940.CrossRefPubMed

77.

Fanouriakis A, Kostopoulou M, Cheema K, Anders H-J, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020:annrheumdis-2020-216924. Doi: https://doi.org/10.1136/annrheumdis-2020-216924.

78.

Tektonidou MG. Antiphospholipid syndrome nephropathy: from pathogenesis to treatment. Front Immunol. 2018;9. https://doi.org/10.3389/fimmu.2018.01181.

79.

Yue C, Li G, Wen Y, Li X, Gao R. Early renin-angiotensin system blockade improved short-term and Longterm renal outcomes in systemic lupus erythematosus patients with antiphospholipid-associated nephropathy. J Rheumatol. 2018;45:655–62. https://doi.org/10.3899/jrheum.170561.CrossRefPubMed

80.

Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A. Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab. Hippokratia. 2010;14:215–6.PubMedPubMedCentral

81.

Rymarz A, Niemczyk S. The complex treatment including rituximab in the management of catastrophic antiphospholid syndrome with renal involvement. BMC Nephrol. 2018;19:132. https://doi.org/10.1186/s12882-018-0928-z.CrossRefPubMedPubMedCentral

82.

Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018;27:1552–8. https://doi.org/10.1177/0961203318768890.CrossRefPubMed

83.

•• Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG. Effect of belimumab treatment on antiphospholipid antibodies levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. Ann Rheum Dis. 2019;77:304–7. https://doi.org/10.1136/annrheumdis-2019-216367This post-hoc analysis of two randomized trials in SLE showed no effect of belimumab on antiphospholipid antibody levels over a 12 months follow-up.CrossRef

84.

Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol. 2019;10:449. https://doi.org/10.3389/fimmu.2019.00449.CrossRefPubMedPubMedCentral

85.

Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015;7:26–30. https://doi.org/10.1177/1759720X14554793.CrossRefPubMedPubMedCentral

86.

Kello N, Khoury LE, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Semin Arthritis Rheum. 2019;49:74–83. https://doi.org/10.1002/art.40933.CrossRefPubMed

87.

Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int. 2017;37:1249–55. https://doi.org/10.1007/s00296-017-3686-5.CrossRefPubMed

88.

Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore). 2014;93:e143. https://doi.org/10.1097/MD.0000000000000143.CrossRef

89.

Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noël L-H, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:303–12. https://doi.org/10.1056/NEJMoa1312890.CrossRefPubMed

90.

Dufour I, Venot Q, Aydin S, Demoulin N, Canaud G, Morelle J. mTORC pathway activation and effect of Sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report. Am J Kidney Dis. 2019;S0272-6386:31061–3. https://doi.org/10.1053/j.ajkd.2019.08.032.CrossRef

91.

Seshan SV, Franzke C-W, Redecha P, Monestier M, Mackman N, Girardi G. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood. 2009;114:1675–83. https://doi.org/10.1182/blood-2009-01-199117.CrossRefPubMedPubMedCentral

92.

•• Grenn RC, Yalavarthi S, Gandhi AA, Kazzaz NM, Núñez-Álvarez C, Hernández-Ramírez D, et al. Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome. Ann Rheum Dis. 2017;76:450–7. https://doi.org/10.1136/annrheumdis-2016-209442This is the first study that described type 1 interferon signature in primary APS promoting endothelial progenitor function, with a potential implication to novel treatment approaches such as anti-interferon drugs.CrossRefPubMed

93.

Palli E, Kravvariti E, Tektonidou MG. Type I Interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations. Front Immunol 2019;10. Doi: https://doi.org/10.3389/fimmu.2019.00487.

94.

Xourgia E, Tektonidou MG. Type I interferon gene expression in antiphospholipid syndrome: pathogenetic, clinical and therapeutic implications. J Autoimmun. 2019;104:102311. https://doi.org/10.1016/j.jaut.2019.102311.CrossRefPubMed

95.

•• Flessa C-M, Vlachiotis S, Nezos A, Andreakos E, Mavragani CP, Tektonidou MG. Independent association of low IFNλ1 gene expression and type I IFN score/IFNλ1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. Clin Immunol. 2019;209:108265. https://doi.org/10.1016/j.clim.2019.108265This is the first study that examined the interferon lambda gene expression in patients with primary APS.CrossRefPubMed

96.

Francès C, Niang S, Laffitte E, le Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785–93. https://doi.org/10.1002/art.21041.CrossRefPubMed

97.

Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol. 2005;23:499–504.PubMed

98.

Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, Kelekis DA, Moutsopoulos HM. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum. 2003;48:732–6. https://doi.org/10.1002/art.10835.CrossRefPubMed

99.

Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166:2278–84. https://doi.org/10.1001/archinte.166.20.2278.CrossRefPubMed

100.

Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 2006;33:2379–82.PubMed

101.

Kraemer M, Linden D, Berlit P. The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review. J Neurol. 2005;252:1155–66. https://doi.org/10.1007/s00415-005-0967-9.CrossRefPubMed

102.

Bersano A, Morbin M, Ciceri E, Bedini G, Berlit P, Herold M, et al. The diagnostic challenge of Divry van Bogaert and Sneddon syndrome: report of three cases and literature review. J Neurol Sci. 2016;364:77–83. https://doi.org/10.1016/j.jns.2016.03.011.CrossRefPubMed

103.

Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140:131–5. https://doi.org/10.1046/j.1365-2133.1999.02622.x.CrossRefPubMed

104.

Grasland A, Crickx B, Blanc M, Pouchot J, Vinceneux P. Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies. Ann Med Interne (Paris). 2000;151:408–10.

105.

• Micieli R, Alavi A. Treatment for livedoid vasculopathy: a systematic review. JAMA Dermatol. 2018;154:193–202. https://doi.org/10.1001/jamadermatol.2017.4374Systematic review of 29 case series reporting on available treatment approaches for livedoid vasculopathy.CrossRefPubMed

106.

So BJ, Park JB, Yoo MG, Kim I-H, Son SW. Successful treatment of livedoid vasculitis with primary antiphospholipid syndrome by using aspirin and low dose warfarin combination therapy. Ann Dermatol. 2015;27:614–5. https://doi.org/10.5021/ad.2015.27.5.614.CrossRefPubMedPubMedCentral

107.

Yu WY-H, Bhutani T, Kornik R, Pincus LB, Mauro T, Rosenblum MD, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153:309–14. https://doi.org/10.1001/jamadermatol.2016.4821.CrossRefPubMedPubMedCentral

108.

Sharma Y, Humphreys K, Thompson C. Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report. J Med Case Rep. 2018;12:226. https://doi.org/10.1186/s13256-018-1753-5.CrossRefPubMedPubMedCentral

109.

Kumar A, Sharma A, Agarwal A. Livedoid vasculopathy presenting with leg ulcers. Rheumatol Oxf Engl. 2019;58:2076. https://doi.org/10.1093/rheumatology/kez126.CrossRef

110.

Figurelli J, Kolsi K, Franchet C, Delavigne K, Soule-Tholy M, Jouve E, et al. Breast pyoderma gangrenosum: a rare postoperative complication of antiphospholipid antibody syndrome. Breast J. 2019;25:498–9. https://doi.org/10.1111/tbj.13253.CrossRefPubMed

111.

Cañas CA, Durán CE, Bravo JC, Castaño DE, Tobón GJ. Leg ulcers in the antiphospholipid syndrome may be considered as a form of pyoderma gangrenosum and they respond favorably to treatment with immunosuppression and anticoagulation. Rheumatol Int. 2010;30:1253–7. https://doi.org/10.1007/s00296-010-1418-1.CrossRefPubMed

112.

Hod T, Lazarov A, Edelstein E, Levy Y. A huge pyoderma gangrenosum-like lesion as a presenting sign of antiphospholipid antibody syndrome. J Rheumatol. 2009;36:1557–9. https://doi.org/10.3899/jrheum.081182.CrossRefPubMed

113.

Santos G, João A, Sousa L. Leg ulcers in antiphospholipid syndrome secondary to systemic lupus erythematosus treated with intravenous immunoglobulin. J Dermatol Case Rep. 2014;8:38–41. https://doi.org/10.3315/jdcr.2014.1169.CrossRefPubMedPubMedCentral

114.

Saifan C, Saad M, El-Charabaty E, El-Sayegh S. Warfarin-induced calciphylaxis: a case report and review of literature. Int J Gen Med. 2013;6:665–9. https://doi.org/10.2147/IJGM.S47397.CrossRefPubMedPubMedCentral

115.

Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc JINS. 1997;3:377–86.CrossRefPubMed

116.

Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999;42:728–34.CrossRefPubMed

117.

Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–41.CrossRefPubMed

118.

Whitelaw DA, Spangenberg JJ, Rickman R, Hugo FH, Roberts M. The association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus. 1999;8:444–8. https://doi.org/10.1177/096120339900800606.CrossRefPubMed

119.

Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21:251–64. https://doi.org/10.1076/jcen.21.2.251.931.CrossRefPubMed

120.

Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke. 1995;26:749–54. https://doi.org/10.1161/01.str.26.5.749.CrossRefPubMed

121.

Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, et al. β2-glycoprotein I (β2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol. 1999;115:214–9. https://doi.org/10.1046/j.1365-2249.1999.00770.x.CrossRefPubMedPubMedCentral

122.

Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8:127–33. https://doi.org/10.1191/096120399678847524.CrossRefPubMed

123.

Katzav A, Menachem A, Maggio N, Pollak L, Pick CG, Chapman J. IgG accumulates in inhibitory hippocampal neurons of experimental antiphospholipid syndrome. J Autoimmun. 2014;55:86–93. https://doi.org/10.1016/j.jaut.2014.07.006.CrossRefPubMed

124.

Gris J-C, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015;135(Suppl 1):S56–9. https://doi.org/10.1016/S0049-3848(15)50445-3.CrossRefPubMed

125.

•• Fleetwood T, Cantello R, Comi C. Antiphospholipid syndrome and the neurologist: from pathogenesis to therapy. Front Neurol. 2018;9:1001. https://doi.org/10.3389/fneur.2018.01001Review of pathogenetic mechanisms and treatment approaches of neurological manifestations in antiphospholipid syndrome.CrossRefPubMedPubMedCentral

126.

Homayoon N, Schwingenschuh P, Hofer E, Katschnig-Winter P, Schmidt R. Anticardiolipin antibodies are associated with cognitive dysfunction in stroke-free individuals. Eur J Neurol. 2014;21:427–32, e21-22. https://doi.org/10.1111/ene.12316.CrossRefPubMed

127.

Arvanitakis Z, Capuano AW, Brey R, Fleischman DA, Arfanakis K, Buchman AS, et al. Antiphospholipid antibodies: cognitive and motor decline, neuroimaging and neuropathology. Neuroepidemiology. 2019;53:100–7. https://doi.org/10.1159/000342761.CrossRefPubMed

128.

Ricarte IF, Dutra LA, Barsottini OGP, de Souza AWS, de Andrade DCO, Mangueira C, et al. Transcranial Doppler findings in antiphospholipid syndrome. Lupus. 2019;28:483–91. https://doi.org/10.1177/0961203319828833.CrossRefPubMed

129.

Bucci T, Menichelli D, Pignatelli P, Triggiani M, Violi F, Pastori D. Relationship of Antiphospholipid antibodies to risk of dementia: a systematic review. J Alzheimers Dis JAD. 2019;69:561–76. https://doi.org/10.3233/JAD-181294.CrossRefPubMed

130.

Zamproni LN, Rubert MCS, Zétola VF, Mader-Joaquim MJ, Lange MC. Cognitive impairment and antiphospholipid syndrome: is paradoxical embolism the rule? Neurol Res. 2013;35:890–4. https://doi.org/10.1179/1743132813Y.0000000237.CrossRefPubMed

131.

Ricarte IF, Dutra LA, Abrantes FF, Toso FF, Barsottini OGP, Silva GS, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus. 2018;27:1404–14. https://doi.org/10.1177/0961203318776110.CrossRefPubMed

132.

Bubb MR. Efficacy of warfarin anticoagulation and incident dementia: does cognitive impairment reduce efficacy? Mayo Clin Proc. 2018;93:1687. https://doi.org/10.1016/j.mayocp.2018.08.019.CrossRefPubMed

133.

Roie EV, Labarque V, Renard M, Van Geet C, Gabriëls L. Obsessive-compulsive behavior as presenting symptom of primary antiphospholipid syndrome. Psychosom Med. 2013;75:326–30. https://doi.org/10.1097/PSY.0b013e31828acfbc.CrossRefPubMed

134.

Hughes GRV. Migraine, memory loss, and “multiple sclerosis”. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad Med J. 2003;79:81–3. https://doi.org/10.1136/pmj.79.928.81.CrossRefPubMedPubMedCentral

135.

Khayyat S, Ebrahem R, Al-Hadeethi D, Al-Obaidi A, Shahouri S. Cerebellar atrophy and neurocognitive disorder as primary presentation of antiphospholipid syndrome in a young male. Kans J Med. 2019;12:22–3.CrossRefPubMedPubMedCentral

136.

Yokoyama K, Mori M, Yoshida A. Mycophenolate mofetil therapy for two cases of antiphospholipid antibody-associated chorea. Mod Rheumatol. 2018;28:709–11. https://doi.org/10.3109/14397595.2015.1134035.CrossRefPubMed

137.

Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23:1449–51. https://doi.org/10.1177/0961203314551084.CrossRefPubMed

138.

Carecchio M, Comi C, Varrasi C, Stecco A, Sainaghi PP, Bhatia K, et al. Complex movement disorders in primary antiphospholipid syndrome: a case report. J Neurol Sci. 2009;281:101–3. https://doi.org/10.1016/j.jns.2009.03.011.CrossRefPubMed

139.

Aulestia NP, Giráldez CR, Luis Marenco de la Fuente J, Tellado MR. 66 Neurologic manifestations of the antiphospholipid syndrome and response to hydroxychloroquine: a descriptive study. Abstracts, Lupus Foundation of America; 2019, p. A48.2-A49. Doi: https://doi.org/10.1136/lupus-2019-lsm.66.

140.

McHugh J. Systemic lupus erythematosus: IFN drives synapse loss via microglia. Nat Rev Rheumatol. 2017;13:449. https://doi.org/10.1038/nrrheum.2017.109.CrossRefPubMed

141.

de Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke. Clin Dev Immunol. 2012;2012:1–7. https://doi.org/10.1155/2012/981519.CrossRef

142.

Noureldine MHA, Harifi G, Berjawi A, Haydar AA, Nader M, Elnawar R, et al. Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? Lupus. 2016;25:1397–411. https://doi.org/10.1177/0961203316651747.CrossRefPubMed

143.

Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von Landenberg P, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–8.PubMed

144.

Krause I, Leibovici L, Blank M, Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus. 2007;16:176–80. https://doi.org/10.1177/0961203306075977.CrossRefPubMed

145.

Hopia L, Andersson M, Svenungsson E, Khademi M, Piehl F, Tomson T. Epilepsy in systemic lupus erythematosus: prevalence and risk factors. Eur J Neurol. 2020;27:297–307. https://doi.org/10.1111/ene.14077.CrossRefPubMed

146.

Liou HH, Wang CR, Chen CJ, Chen RC, Chuang CY, Chiang IP, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus. 1996;5:307–12. https://doi.org/10.1177/096120339600500412.CrossRefPubMed

147.

Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci. 1994;54:1119–25. https://doi.org/10.1016/0024-3205(94)00422-6.CrossRefPubMed

148.

Islam MA, Alam F, Cavestro C, Calcii C, Sasongko TH, Levy RA, et al. Antiphospholipid antibodies in epilepsy: a systematic review and meta-analysis. Autoimmun Rev. 2018;17:755–67. https://doi.org/10.1016/j.autrev.2018.01.025.CrossRefPubMed

149.

Xu MY. Poststroke seizure: optimising its management. Stroke Vasc Neurol. 2019;4:48–56. https://doi.org/10.1136/svn-2018-000175.CrossRefPubMed

Title: Management of Non-criteria Manifestations in Antiphospholipid Syndrome
Authors: Eleni Xourgia
Maria G. Tektonidou
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Antiphospholipid Syndrome
Thrombocytopenia
Epilepsy
Antiphospholipid Syndrome
Hemolytic Anemia
Published in: Current Rheumatology Reports / Issue 9/2020
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-020-00935-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of the Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 9/2020

Work Disability in Axial Spondyloarthritis

Management of Myocarditis in Myositis: Diagnosis and Treatment

Is Axial Spondyloarthritis More Common Than Rheumatoid Arthritis?

The Impact of Obesity on Disease Activity and Treatment Response in Rheumatoid Arthritis

JAK Inhibitors: What Is New?

Visualization of Enthesitis by Ultrasound: a Key Diagnostic Tool in Spondyloarthropathy Diagnosis and Management

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage